New drug duo aims to outsmart resistant lymphoma

NCT ID NCT07684950

Not yet recruiting Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 study tests whether combining two oral drugs — lisaftoclax and pirtobrutinib — can shrink or control mantle cell lymphoma in adults whose cancer has stopped responding to or caused intolerance to prior BTK-targeted treatments. Participants take both pills daily until the disease worsens or side effects become unacceptable. The study will measure how many patients achieve a complete response (cancer disappearance) at six months and track safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lisaftoclax and pirtobrutinib
What this could lead to: If successful, this combination could offer a new treatment option for people with mantle cell lymphoma whose cancer has stopped responding to standard BTK inhibitors.
What could go wrong: This is an early-phase study with only 45 participants, so results may not apply broadly. The drugs may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Show contact details

Locations

Henan Cancer Hospital

Zhengzhou, Henan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.